Article Versions Notes

De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC. The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells. 2022; 11(18):2866. https://doi.org/10.3390/cells11182866

De Azevedo, Justine, Jana Mourtada, Cyril Bour, Véronique Devignot, Philippe Schultz, Christian Borel, Erwan Pencreach, Georg Mellitzer, Christian Gaiddon, and Alain C. Jung. 2022. "The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response" Cells 11, no. 18: 2866. https://doi.org/10.3390/cells11182866

De Azevedo, J., Mourtada, J., Bour, C., Devignot, V., Schultz, P., Borel, C., Pencreach, E., Mellitzer, G., Gaiddon, C., & Jung, A. C. (2022). The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells, 11(18), 2866. https://doi.org/10.3390/cells11182866